Laboratorio Italiano Biochimico Farmaceutico Lisapharma SPA – FDA 483, Mar 1, 2022
An FDA inspection of Laboratorio Italiano Biochimico Farmaceutico Lisapharma SPA in Erba, Italy, revealed significant deficiencies in aseptic processing and quality control for sterile drug manufacturing. Observations included inadequate procedures to prevent microbiological contamination, ineffective cleaning and disinfection, and failures in investigating discrepancies and maintaining complete laboratory records. These issues indicate a need for comprehensive improvements in the firm's quality systems to ensure the sterility and quality of its injectable drug products.
- Inspection date
- March 1, 2022
- Product type
- drugs
ID · 583ff28a-2b3c-4e07-a0c3-c3d8c369f768
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.